Target	Target Dose Range (Gy EQD2)	Fractionated RT (Gy EQD2)	HDR/LDR Brachytherapy Boost (Gy EQD2)	SABR (Gy EQD2)
Prostate tumor < 50% of prostate volume	(78–168)	(78–113) e.g. 77Gy/35 fractions with concomitant boost to 95Gy/35 fractions [21]	(115–140) intraprostatic boost optional at time of brachytherapy, (125% - GTV)	(92–168) e.g. 35Gy/5 fractions with concomitant boost to 50Gy/5 fractions [22]
Involved pelvic or adjacent PA LNs (up to T12/L1)	(60–86)	(60–74) concomitant integrated or sequential boost (aim as high as possible within dose range while respecting OARs)	na	(65–86) 30–35/5# Concomitant boost
Prostate bed GTV	(70–74)	(70–74) sequential boost only	na	na
Bone metastasis	(66–110)	(66–74) concomitant if adjacent to pelvic RT fields	na	(66–110) 30-40Gy/5# 24Gy/2# (spine only)
Remote LNs	(66–110)	na	na	(66–110) 30-40Gy/5#
Lung mets (peripheral)	(190)	na	na	(190) 48Gy/4#
Lung mets (central)	(86–168)	na	na	(86–168) 35-50Gy/5#
Liver metastasis	(66 or more)	na	na	(66 or more) 30-60Gy/3–5#

For gross disease that has achieved a complete radiographic response to hormone therapy (e.g. enlarged lymph nodes), the original area of the disease should be treated to an EQD2 of 42-56Gy

In general for stereotactic radiotherapy of metastases, a dose of 35 Gy in 5 fractions delivered in a conformal fashion and with dose homogeneity is an effective and safe dose for the majority of non-spine tumour targets. For spine metastases, a dose of 24 Gy in 2 fractions is highly recommended

Radiation therapy details including OAR constraints are available in Appendix